ÂÜÀòÂÒÂ×

Hilary M. Malone, Ph.D., has served as a member of the Board since May 2021. Hilary has over 25 years of experience in global drug development, regulatory and government affairs, manufacturing and commercialization within the pharmaceutical industry. She has served as Chief Executive Officer of a private life sciences company in start-up phase since November 2021. She previously served as Chief Operating Officer and Executive Vice President at Valo Health Inc. from January 2020 to September 2021. Prior to that, Hilary served as the Chief Regulatory Officer and Senior Vice President & Head of Global Regulatory Affairs at Sanofi Inc. (subsidiary of Sanofi SA (Euronext: SAN)). Her previous experience also includes senior regulatory and drug development roles at Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Pfizer Inc. (NYSE:PFE), Wyeth, LLC (acquired by Pfizer Inc.), AstraZeneca plc (LSE: AZN) and GlaxoSmithKline plc (LSE: GSK). Hilary served on the board of Inhibikase Therapeutics (NASDAQ: IKT) from 2016 to 2019. She holds a Ph.D. in Molecular Neuropharmacology and a B.Sc. in Physiology from the University of Dundee, Scotland. She was born in 1965 and is a U.S., U.K., and Irish citizen.

Hilary is Chair of Hansa’s U.S. Committee and member of the Scientific Committee.